ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes

Abstract

This ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri) position paper aims to analyse the complex action of sodium-glucose co-transporter 2 inhibitors at the level of the kidney and cardiovascular system, focusing on the effect that these molecules have shown in the prevention and treatment of heart failure in diabetic and non-diabetic subjects. The goal was pursued by comparing the data generated with pathophysiology studies and with multicentre controlled studies in large populations. In accordance with the analysis carried out in the document, the following recommendations are issued: (i) canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin are molecules recommended for the prevention of heart failure hospitalizations in type 2 diabetic subjects; (ii) canagliflozin and dapagliflozin are recommended for the prevention of heart failure hospitalizations in type 2 diabetic subjects with severe chronic kidney disease, dapagliflozin proved to be safe and effective also in diabetic subjects; and (iii) dapagliflozin and empagliflozin are recommended to reduce the combined risk of heart failure and cardiovascular death in diabetic and non-diabetic subjects with heart failure and reduced ejection fraction.

SGLT2 inhibitors and AMPK: The road to cellular housekeeping?

“…The increased demand for energy can activate AMPK as it senses the low energy state. 21,22 (B) Enhanced fatty acid oxidation:…”

“…This leads to a decrease in blood glucose levels and subsequently an increase in cellular energy demand. The increased demand for energy can activate AMPK as it senses the low energy state 21,22 …”

Italian Association of Hospital Cardiologists practical guidance for sodium–glucose cotransporter 2 inhibitors use in patients with heart failure

“…As highlighted in a recent ANMCO position paper, in the management of patients with heart failure treated with SGLT2-i, the role of the N-terminal fragment of type B natriuretic propeptide in prognosis and as an index of response to therapy is not yet well defined. 26 …”